A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar<scp>PF</scp>‐05280014 with trastuzumab in healthy volunteers (<scp>REFLECTIONS B</scp>327‐01)

Abstract

This study demonstrates PK similarity among PF-05280014, trastuzumab-EU and trastuzumab-US. The safety and immunogenicity profiles observed for the three products in this study are consistent with previous reports for trastuzumab.